Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease

Salvarani, Carlo; Fries, Walter

doi:10.3748/wjg.15.2449

Cited by 109 publications

(78 citation statements)

References 43 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevention of progressive structural damage, preservation/normalization of function, and social participation are key points in treating to target patients affected by SpA [18]. Data from literature showed that the prevalence of peripheral arthritis in IBD patients varies from 11% to 20% and AS prevalence ranged from 3% to 6% [12]. In this study we demonstrated that joint involvement has a prevalence of 18% in a large cohort of 1495 IBD patients evaluated in the same period while ESpA has a prevalence of 9%.…”

Section: Discussionmentioning

confidence: 99%

“…Later, the joint involvement observed in IBD was usually classified mainly into two subsets: axial (including sacroileitis with or without spondylitis) and peripheral [10,11]. Evidence shows that the frequency of the joint involvement in IBD is affected by the criteria applied to define the clinical findings [12]. In particular, axial involvement is present in 2-16% of IBD patients and the prevalence of sacroileitis (asymptomatic and symptomatic) is 12-20%, ranging from 3.9% to 18.9% when HLA-B27 is associated [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients

Conigliaro

Chimenti

Ascolani

et al. 2016

Autoimmunity Reviews

View full text Add to dashboard Cite

Spondyloarthritis (SpA) and inflammatory bowel disease (IBD) are chronic autoinflammatory diseases that partially share the genetic predisposition and the unchecked inflammatory response linking the gut to the joints. The coexistence of both conditions in patients and the increased cross-risk ratios between SpA and IBD strongly suggest a shared pathophysiology. The prevalence of Enteropathic-related Spondyloarthritis (ESpA) in IBD patients shows a wide variation and may be underestimated. It is well accepted that the management of joint pain requires rheumatological expertise in conjunction with gastroenterologist assessment. In this view, we aimed at assessing, in a prospective study performed in a combined Gastro-Intestinal and Rheumatologic "GI-Rhe" clinic: (1) the prevalence of ESpA and other rheumatologic diseases in IBD patients with joint pain; (2) the features of the ESpA population; and (3) the diagnostic delay and the potential impact of the combined assessment. From November 2012 to December 2014, IBD patients with joint pain referring to a dedicated rheumatologist by the IBD-dedicated gastroenterologist were enrolled. Clinical and biochemical evaluations, joint involvement and disease activity assessment, diagnostic delay, and treatment were recorded. IBD patients (n = 269) with joint pain were jointly assessed in the "GI-Rhe" Unit. A diagnosis of ESpA was made in 50.5% of IBD patients with joint pain. ESpA patients showed a peripheral involvement in 53% of cases, axial in 20.6% and peripheral and axial in 26.4% of cases. ESpA patients had a higher prevalence of other autoimmune extra-intestinal manifestations and received more anti-TNF treatment compared with IBD patients. A mean diagnostic delay of 5.2 years was revealed in ESpA patients. Patients with joint disease onset in the 2002-2012 decade had reduced diagnostic delay compared with those with onset in the 1980-1990 and 1991-2001 decades. Diagnostic delay was further reduced for patients with joint onset in the last two years in conjunction with the establishment of the GI-Rhe clinic. Multidisciplinary approach improved management of rheumatic disorders in IBD patients allowing a more comprehensive care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients

Conigliaro

Chimenti

Ascolani

et al. 2016

Autoimmunity Reviews

View full text Add to dashboard Cite

show abstract

“…Peripheral arthropathy (pauciarticular, asymmetrical and migratory) occurs in 10-20% of inflammatory bowel disease (IBD) patients and is characterized by a recurrent nature and a parallel course with CD (11)(12)(13). In contrast, axial arthropathy shows an independent course of CD and includes sacroiliitis, with a prevalence of 12-25%, and ankylosing spondylitis, with a prevalence of 2-16% in Crohn's patients (11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease

Acosta

Lorenzo

Domínguez‐Muñoz

2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Background and aims:Crohn's disease (CD) is commonly associated with inflammatory processes located in organs and systems others than the gut, which are known as extraintestinal manifestations (EIM) of the disease. The aim of this study was to assess the effectiveness of adalimumab (ADA) for the treatment of EIM in patients with CD.Methods: forty two consecutive CD patients with at least one EIM were prospectively included in a open-label study. Patients received ADA (160 mg at week zero, 80 mg at week two and 40 mg every other week) over six months and the effectiveness and safety of ADA for EIMs were assessed. The influence of gender, age, smoking habits, family history of inflammatory bowel disease, phenotype and previous anti-TNF treatment on EIM resolution was also investigated.Results: at month six, 76.2% of the patients showed remission or response in CD (33.3% remission and 42.9% any response). EIM showed a parallel course with CD in most cases, and showed remission or response in 66.7% of patients (38.1% remission and 28.5% any response). Patients with any response of their EIM condition were younger than those with no response (p = 0.04). No relationship was found between sex, tobacco, family history of IBD, phenotype and previous treatment with anti-TNF, and EIM resolution.Conclusions: adalimumab is effective in reducing EIM of CD. Age but not tobacco, CD phenotype and anti-TNF-naïve status appears to influence the response.

show abstract

“…Genetic predisposition and environmental factors have been implicated in the pathogenesis of AS [1,2]. With new and very effective therapeutic approaches, such as biologics becoming available, it is imperative to recognize and treat AS as early as possible in order to prevent disability.…”

Section: Introductionmentioning

confidence: 99%

Anti-mutated citrullinated vimentin (anti-MCV) and anti-65kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis

et al. 2012

View full text Add to dashboard Cite

Introduction: Citrullination as well as anti-citrullinated protein/peptide antibodies (ACPA) have been implicated in the pathogenesis of rheumatoid arthritis (RA). While ACPAs are specific and sensitive markers for RA, there have been hardly any reports regarding ACPAs in ankylosing spondylitis (AS). The possible role of antibodies to Mycobacterial 65 kDa heat shock protein (hsp65) has not been characterized in AS. As new laboratory biomarkers of AS are needed, we investigated the prevalence of anti-mutated citrullinated vimentin (MCV) and anti-hsp65 antibodies in AS. Methods: Altogether 43 AS and 44 healthy controls were included in the study. Anti-MCV and antihsp65 were determined in sera by commercial and in-house ELISA, respectively. Serum autoantibody levels were correlated with ESR, CRP, HLA-B27 status, smoking habits, pain intensity, BASDAI, BASFI and BASMI indices. Results: Patients with AS had significantly higher serum anti-MCV levels (17.3 U/ml, range: 8.3-31.5 U/ml) in comparison to healthy subjects (8.9 U/ml, range: 5.4-13.3 U/ml) (p<0.01). Sixteen of the 43 AS patients (37%) and none of the 44 healthy controls (0%) were anti-MCV positive using the cut-off value recommended by the manufacturer (> 20 U/ml). The mean anti-hsp65 concentration in AS sera was 124.8 AU/ml (range: 27.2-1000 AU/ml), while controls exerted significantly lower anti-hsp65 levels (mean: 51.8 AU/ml; range: 22.5-88.5 AU/ml) (p<0.001). Correlation analysis revealed that both anti-MCV positivity (r=0.613; p=0.012) and absolute serum anti-MCV levels (r=0,553; p=0.021) correlated with anti-hsp65 levels. Anti-MCV positivity also correlated with ESR (r= 0.437; p=0.03). Conclusions: Anti-MCV and anti-hsp65 may be novel biomarkers in AS . 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64

show abstract

Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease

Cited by 109 publications

References 43 publications

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease

Anti-mutated citrullinated vimentin (anti-MCV) and anti-65kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis

Contact Info

Product

Resources

About